Identification of Novel Substrates for Human Cytochrome P450 2J2

Pfizer Global Research & Development, 10646 Science Center Dr., San Diego, CA 92121, USA.
Drug metabolism and disposition: the biological fate of chemicals (Impact Factor: 3.74). 11/2009; 38(2):347-56. DOI: 10.1124/dmd.109.030270
Source: PubMed

ABSTRACT Several antihistamine drugs including terfenadine, ebastine, and astemizole have been identified as substrates for CYP2J2. The overall importance of this enzyme in drug metabolism has not been fully explored. In this study, 139 marketed therapeutic agents and compounds were screened as potential CYP2J2 substrates. Eight novel substrates were identified that vary in size and overall topology from relatively rigid structures (amiodarone) to larger complex structures (cyclosporine). The substrates displayed in vitro intrinsic clearance values ranging from 0.06 to 3.98 mul/min/pmol CYP2J2. Substrates identified for CYP2J2 are also metabolized by CYP3A4. Extracted ion chromatograms of metabolites observed for albendazole, amiodarone, astemizole, thioridazine, mesoridazine, and danazol showed marked differences in the regioselectivity of CYP2J2 and CYP3A4. CYP3A4 commonly metabolized compounds at multiple sites, whereas CYP2J2 metabolism was more restrictive and limited, in general, to a single site for large compounds. Although the CYP2J2 active site can accommodate large substrates, it may be more narrow than CYP3A4, limiting metabolism to moieties that can extend closer toward the active heme iron. For albendazole, CYP2J2 forms a unique metabolite compared with CYP3A4. Albendazole and amiodarone were evaluated in various in vitro systems including recombinant CYP2J2 and CYP3A4, pooled human liver microsomes (HLM), and human intestinal microsomes (HIM). The Michaelis-Menten-derived intrinsic clearance of N-desethyl amiodarone was 4.6 greater in HLM than in HIM and 17-fold greater in recombinant CYP3A4 than in recombinant CYP2J2. The resulting data suggest that CYP2J2 may be an unrecognized participant in first-pass metabolism, but its contribution is minor relative to that of CYP3A4.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Microbial metabolism of danazol (17alpha-pregna-2,4-dien-20-yno[2,3-d]isoxazol-17beta-ol) by Beauveria bassiana ATCC 7159 and Glyocladium viride ATCC 10097 afforded four metabolites. The isolated metabolites were identified by different spectroscopic techniques as 6beta-hydroxy danazol, which is a not yet reported danazol metabolite, 17beta-hydroxy-17alpha-pregn-4-en-20-yn-3-one (ethisterone) and 17beta-hydroxy-2alpha-(hydroxymethyl)-17alpha-pregn-4-en-20-yn-3-one (2alpha-hydroxymethyl ethisterone), which represent the major danazol metabolites detected in human urine. The last metabolite, 6beta,17beta-dihydroxy-2-(hydroxymethyl)-17alpha-pregna-1,4-dien-20-yn-3-one, is also a minor human metabolite, for which the NMR data are described here for the first time. The metabolites were isolated in quantities that allowed their use for direct comparison in routine doping analysis.
    Zeitschrift fur Naturforschung C 05/2014; 69(5-6):245-52. DOI:10.5560/ZNC.2013-0135 · 0.57 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cytochrome P450 4F12 is a drug metabolizing enzyme that is primarily expressed in the liver, kidney, colon, small intestine and heart. The properties of CYP4F12 that may impart an increased catalytic selectivity (decreased promiscuity) were explored through in vitro metabolite elucidation, kinetic isotope effect experiments and computational modeling of the CYP4F12 active site. Using astemizole as a probe substrate for CYP4F12 and CYP3A4, it was observed that while CYP4F12 favored astemizole O-demethylation as the primary route of metabolism, CYP3A4 was capable of metabolizing astemizole at multiple sites on the molecule. Deuteration of astemizole at the site of O-demethylation resulted in an isotope effect of 7.1 as well as an 8.3-fold decrease in the rate of clearance for astemizole by CYP4F12. Conversely, while an isotope effect of 3.8 was observed for the formation of the O-desmethyl metabolite when deuterated astemizole was metabolized by CYP3A4, there was no decrease in the clearance of astemizole. Development of a homology model of CYP4F12 based on the crystal structure of cytochrome P450 BM3 predicted an active site volume for CYP4F12 that was approximately 76% of the active site volume of CYP3A4. As predicted, multiple favorable binding orientations were available for astemizole docked into the active site of CYP3A4, but only a single binding orientation with the site of O-demethylation oriented towards the heme was identified for CYP4F12. Overall, it appears that while CYP4F12 may be capable of binding similar ligands to other cytochrome P450 enzymes such as CYP3A4, the ability to achieve catalytically favorable orientations may be inherently more difficult due to the increased steric constraints of the CYP4F12 active site.
    Drug metabolism and disposition: the biological fate of chemicals 07/2014; 42(10). DOI:10.1124/dmd.114.059626 · 3.74 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The impact of gastrointestinal (GI) processing and first pass metabolism on danazol oral bioavailability (BA) was evaluated after administration of self-emulsifying drug delivery systems (SEDDS) in the rat. Danazol absolute BA was determined following oral and intraduodenal (ID) administration of LFCS class IIIA medium chain (MC) formulations at high (SEDDSH-III) and low (SEDDSL-III) drug loading and a lipid free LFCS class IV formulation (SEDDS-IV). Experiments were conducted in the presence and absence of ABT (1-aminobenzotriazole) to evaluate the effect of first pass metabolism. A series of modified in vitro lipolysis tests were developed to better understand the in vivo processing of SEDDS in the rat. Danazol BA was low (<13%) following oral and ID administration of either SEDDS. Increasing drug loading, ID rather than oral administration, and administration of SEDDS-IV rather than SEDDS-III led to higher oral BA. After pretreatment with ABT, however, danazol oral BA significantly increased (e.g., 60% compared to 2% after administration of SEDDSL-III), no effect was observed on increasing drug loading, and differences between SEDDS-III and -IV were minimal. In vitro digestion models based on the lower enzyme activity and lower dilution conditions expected in the rat resulted in significantly reduced danazol precipitation from SEDDS-III or SEDDS-IV on initiation of digestion. At the doses administered here (4-8 mg/kg), the primary limitation to danazol oral BA in the rat was first pass metabolism, and the fraction absorbed was >45% after oral administration of SEDDS-III or SEDDS-IV. In contrast, previous studies in dogs suggest that danazol BA is less dependent on first pass metabolism and more sensitive to changes in formulation processing. In vitro digestion models based on likely rat GI conditions suggest less drug precipitation on formulation digestion when compared to equivalent dog models, consistent with the increases in in vivo exposure (fraction absorbed) seen here in ABT-pretreated rats.
    Molecular Pharmaceutics 09/2014; 11(11). DOI:10.1021/mp500197b · 4.79 Impact Factor